JP2009159869A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009159869A5 JP2009159869A5 JP2007341430A JP2007341430A JP2009159869A5 JP 2009159869 A5 JP2009159869 A5 JP 2009159869A5 JP 2007341430 A JP2007341430 A JP 2007341430A JP 2007341430 A JP2007341430 A JP 2007341430A JP 2009159869 A5 JP2009159869 A5 JP 2009159869A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- nucleotide sequence
- znf143
- polynucleotide
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 26
- 239000002773 nucleotide Substances 0.000 claims 25
- 108091033319 polynucleotide Proteins 0.000 claims 19
- 102000040430 polynucleotide Human genes 0.000 claims 19
- 239000002157 polynucleotide Substances 0.000 claims 19
- 239000000126 substance Substances 0.000 claims 18
- 101000759226 Homo sapiens Zinc finger protein 143 Proteins 0.000 claims 15
- 102100023389 Zinc finger protein 143 Human genes 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 11
- 230000003796 beauty Effects 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 4
- 101150093411 ZNF143 gene Proteins 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 230000009368 gene silencing by RNA Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000008685 targeting Effects 0.000 claims 4
- 108020004635 Complementary DNA Proteins 0.000 claims 3
- 230000009702 cancer cell proliferation Effects 0.000 claims 3
- 230000005907 cancer growth Effects 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 229940104302 cytosine Drugs 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010175 gallbladder cancer Diseases 0.000 claims 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- NOIRDLRUNWIUMX-UHFFFAOYSA-N 2-amino-3,7-dihydropurin-6-one;6-amino-1h-pyrimidin-2-one Chemical group NC=1C=CNC(=O)N=1.O=C1NC(N)=NC2=C1NC=N2 NOIRDLRUNWIUMX-UHFFFAOYSA-N 0.000 claims 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007341430A JP2009159869A (ja) | 2007-12-28 | 2007-12-28 | 癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法 |
| PCT/JP2008/073817 WO2009084668A1 (ja) | 2007-12-28 | 2008-12-26 | 癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法 |
| EP08869206A EP2246069A4 (en) | 2007-12-28 | 2008-12-26 | METHOD FOR INHIBITING CANCER CELL PROGRAMMING, PROLIFERATION INHIBITOR AND SCREENING METHOD |
| US12/810,696 US8580758B2 (en) | 2007-12-28 | 2008-12-26 | Method of inhibiting cancer cell proliferation, proliferation inhibitor and screening method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007341430A JP2009159869A (ja) | 2007-12-28 | 2007-12-28 | 癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009159869A JP2009159869A (ja) | 2009-07-23 |
| JP2009159869A5 true JP2009159869A5 (https=) | 2011-02-03 |
Family
ID=40824381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007341430A Pending JP2009159869A (ja) | 2007-12-28 | 2007-12-28 | 癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8580758B2 (https=) |
| EP (1) | EP2246069A4 (https=) |
| JP (1) | JP2009159869A (https=) |
| WO (1) | WO2009084668A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2453724A4 (en) | 2009-07-06 | 2014-11-05 | Fujikura Ltd | IMPLEMENTATION PLATE AND METHOD FOR THE PRODUCTION THEREOF |
| AU2017264192B2 (en) | 2016-05-10 | 2023-08-03 | National University Corporation Tokyo Medical And Dental University | Expression inhibitor of inflammation promoting factors, screening method for active ingredient thereof, expression cassette useful for said method, diagnostic agent and diagnosis method |
| KR102715821B1 (ko) * | 2017-11-09 | 2024-10-10 | 고쿠리츠 다이가쿠호우징 도쿄이카시카다이가쿠 | 암 촉진 인자 발현 억제제, 그 유효 성분의 스크리닝 방법, 그 방법에 유용한 발현 카세트, 진단약, 및 진단 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576759B2 (en) | 1999-02-10 | 2003-06-10 | Pangene Corporation | Antisense inhibition of RAD51 |
| WO2003082269A1 (en) | 2002-03-29 | 2003-10-09 | The Board Of Trustees Of The Leland Stanford Junior University | Use of statins and other immunomodulatory agents in the treatment of autoimmune disease |
| WO2003105761A2 (en) | 2002-06-12 | 2003-12-24 | Research Development Foundation | Immunotoxin as a therapeutic agent and uses thereof |
| GB0228337D0 (en) | 2002-12-05 | 2003-01-08 | Yorkshire Cancer Res Campaign | Replication protein |
-
2007
- 2007-12-28 JP JP2007341430A patent/JP2009159869A/ja active Pending
-
2008
- 2008-12-26 US US12/810,696 patent/US8580758B2/en not_active Expired - Fee Related
- 2008-12-26 WO PCT/JP2008/073817 patent/WO2009084668A1/ja not_active Ceased
- 2008-12-26 EP EP08869206A patent/EP2246069A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pisignano et al. | Going circular: history, present, and future of circRNAs in cancer | |
| Barbieri et al. | Role of RNA modifications in cancer | |
| Fang et al. | A novel circular RNA, circFAT1 (e2), inhibits gastric cancer progression by targeting miR-548g in the cytoplasm and interacting with YBX1 in the nucleus | |
| Xu et al. | MALAT-1: a long non-coding RNA and its important 3'end functional motif in colorectal cancer metastasis | |
| Qin et al. | MicroRNA-221 promotes colorectal cancer cell invasion and metastasis by targeting RECK | |
| Preskill et al. | SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers | |
| Liu et al. | Overexpressed miR-494 down-regulates PTEN gene expression in cells transformed by anti-benzo (a) pyrene-trans-7, 8-dihydrodiol-9, 10-epoxide | |
| CN103930563B (zh) | 用于预测癌症复发的方法和装置 | |
| JP5960060B2 (ja) | 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法 | |
| Xu et al. | MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin α5 | |
| Shen et al. | Circular RNAs: an emerging landscape in tumor metastasis | |
| Jiang et al. | miR-211 suppresses hepatocellular carcinoma by downregulating SATB2 | |
| JP2008532477A5 (https=) | ||
| JP2009502115A5 (https=) | ||
| JP2012518997A (ja) | 喫煙未経験者におけるマイクロｒｎａ、ならびに関連する材料および方法 | |
| Chou et al. | MiR-193a-5p and-3p play a distinct role in gastric cancer: miR-193a-3p suppresses gastric cancer cell growth by targeting ETS1 and CCND1 | |
| Babin et al. | From circRNAs to fusion circRNAs in hematological malignancies | |
| JP2010508042A5 (https=) | ||
| CA2690749A1 (en) | Oncogenic all-1 fusion proteins for targeting drosha-mediated microrna processing | |
| JP2012501164A5 (https=) | ||
| Sandhu et al. | Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment | |
| Pang et al. | RETRACTED ARTICLE: Long noncoding RNA SNHG16 silencing inhibits the aggressiveness of gastric cancer via upregulation of microRNA-628-3p and consequent decrease of NRP1 | |
| WO2010011281A3 (en) | Methods and compositions for the diagnosis and treatment of cancer | |
| Jiang et al. | Epigenetic loss of CDH1 correlates with multidrug resistance in human hepatocellular carcinoma cells | |
| Nana-Sinkam et al. | MicroRNA in chronic lymphocytic leukemia: transitioning from laboratory-based investigation to clinical application |